Login
Register
Need Help?
ABOUT
ABOUT THE EGA
EGA
Privacy Notice
Security
Team
STATISTICS
Bibliography
Growth
Community
Archive
Distribution
Catalog
PROJECTS AND FUNDERS
Projects
Funders
GA4GH
Federated EGA
Beacon
DISCOVERY
CATALOGUE
Studies
Datasets
DACs
Synthetic Data
METADATA
Search Box
Public Metadata API
SUBMISSION
DATA
File preparation
Uploading files
METADATA
EGA Schema
Sequencing & Phenotype
Submitter Portal
Submitter Portal API
Array
Programmatic Submission XML
ACCESS
DATA ACCESS COMMITTEE
What is a DAC?
Best Practices
DAC Portal
Data Use Conditions
REQUEST DATA
How to request data?
Quality Control Reports
DOWNLOAD
Metadata
Files
PyEGA3
Live Outbox
Visualisation
FUSE Client
EGA QuickView
Tips on how to search
DACs
EGAC00001002472
DAC for cfTrack study
Request Access
This DAC controls 1 dataset
Dataset ID
Description
Technology
Samples
EGAD00001008454
We also collected samples from 8 NSCLC patients and 4 ovarian cancer patients and. For all 8 NSCLC patients, a tumor biopsy sample, a WBC sample, and three plasma samples were collected. For all 4 ovarian cancer patients, a WBC sample and two serum samples were collected. We collected tumor tissue sample from one ovarian cancer patient (OV4). The cfDNA was extracted from their plasma samples using the QIAamp circulating nucleic acid kit from QIAGEN (Germantown, MD). For serum cfDNA, ampure XP beads size selection was further performed to eliminate gDNA contamination. In brief, 0.5 volume of beads were first added to the cfDNA samples. After incubation, the supernatant was transferred to a new tube and an additional 2.0 volume of beads were added. After 80% ethanol wash, cfDNA was eluted from the beads. FA assays (Agilent Technologies) were performed to rule out the contamination of gDNA in the size selected samples. The cfDNA WES library of all patients and the genomic DNA WES library of the 4 ovarian cancer patients were constructed with the SureSelect XT HS kit from Agilent Technologies (Santa Clara, CA) according to the manufacturer’s protocol. In brief, 10ng of cfDNA was used as input material. After end repair/dA-tailing of cfDNA, the adaptor was ligated. The ligation product was purified with Ampure XP beads (Beckman-Coulter, Atlanta, GA) and the adaptor-ligated library was amplified with index primer in 10-cycle PCR. The amplified library was purified again with Ampure XP beads, and the amount of amplified DNA was measured using the Qubit 1xdsDNA HS assay kit (ThermoFisher, Waltham, MA). 700-1000 ng of DNA sample was hybridized to the capture library and pulled down by streptavidin-coated beads. After washing the beads, the DNA library captured on the beads was re-amplified with 10-cycle PCR. The final libraries were purified by Ampure XP beads. The library concentration was measured by Qubit, and the quality was further examined with Agilent Bioanalyzer before the final step of 2x150bp paired-end sequencing at an average coverage of 200. Whole-exome capture libraries of genomic DNA from the 8 NSCLC patients were constructed via Roche SeqCap EZ Exome V6 (Roche). Enriched exome libraries were sequenced on the Illumina HiSeq 3000 platform (Illumina) to generate 2x100bp paired-end reads at an average coverage of 200.
HiSeq X Ten
Illumina HiSeq 3000
53